Nuvalent
preclinical is a brain penetrant selective inhibitor with the potential to avoid related adverse events | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
14 of 52
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
preclinical characterization demonstrates desired target product profile broad activity on her alterations including her exon ins activating point mutations and amplified wild type her i greater selectivity for her mutations over than pan inhibitors selectivity index more active for her a phospho in a phospho her or viability wild type phospho her viability her her her her her her her her her her her phospho her her knock in her her her her her her her phospho a data similar to observations for brain exposure rats han rats single dose hour no head to head clinical studies have been conducted for currently approved or investigational therapies versus above data from studies her her exon insertion half maximal inhibitory concentration orally source sun | Nuvalent
Investor Presentation
April 2024
preclinical characterization demonstrates desired target product profile in activity wild type mutant brain penetrance avoiding inhibition sub activity in day cell viability assays data similar to observations for selectivity for and over we a we a a a i a a a i a expressing or mutant fusion wild type han rats single dose hour more active for me more active for a selectivity index head to head clinical studies comparing with currently approved or investigational therapies have not been conducted above data from studies bid twice daily half maximal inhibitory concentration patient derived cell line orally stimulated phosphorylation sources a cancer a a | Nuvalent
Investor Presentation
April 2024
preclinical characterization demonstrates desired target product profile brain penetrant with the potential to avoid related adverse events brain penetrance avoiding inhibition data similar to observations for selective inhibition of alk and alk mutants over i a a a i a han rats single dose hour more active for alk more active for a a a a in a selectivity index alk selectivity for alk over no resistance mutations a a a head to head clinical studies comparing with currently approved or investigational therapies have not been conducted central nervous system half maximal inhibitory concentration orally stimulated phosphorylation source lin a data presented here reflect updated values following additional repeat testing | Nuvalent
Investor Presentation
February 2024
preclinical characterization demonstrates desired target product profile potent inhibition of her and her mutations in cell based phosphorylation and viability assays greater selectivity for her mutations over than pan inhibitors data similar to observations for i we assays viability assays assay her her her her exon insertion mutations such as her and her induce constitutive kinase activation more active for her to more active for selectivity index i a a a i a han rats single dose hour no head to head clinical studies have been conducted for currently approved or investigational therapies versus above data from studies her her exon insertion half maximal inhibitory concentration orally source | Nuvalent
Related slides by other companies
23andMe
Investor Day
January 2022
preclinical data supports combining with and inhibitors | 23andMe
Kymera
Investor Presentation
November 2023
degrader best in class potential in immune inflammation an | Kymera
Kymera
Investor Presentation
November 2023
clinical and near term clinical pipeline of novel protein degraders | Kymera
23andMe
Investor Presentation
February 2022
preclinical data supports combining with and inhibitors | 23andMe
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io